No Data
BeiGene Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results.
Star Evening Report | BEIGENE expects revenue of 35.2-38.1 billion yuan in 2025. Huazhu High-Tech Shareholders intend to reduce their Shareholding by no more than 2%.
① Two departments: Increase financial support for charging infrastructure. ② Zhejiang is piloting the use of quadrupedal robots in the civil aviation sector for the first time. ③ Lei Jun: R&D investment is expected to reach 30 billion yuan by 2025.
ACADIA Pharmaceuticals Analyst Ratings
BEIGENE's revenue grew by 56.2% in 2024, with Global research and development accelerating | Earnings Reports insights.
Thanks to the sales growth of the core products Baiyueze (Zebutinib capsules) and Baizean (Trelelimumab), BEIGENE's total operating revenue for the year 2024 reached 27.214 billion yuan, with losses narrowing compared to the same period last year.
Corcept Therapeutics Analyst Ratings
Earnings Scheduled For February 27, 2025